Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. - Test2 - elhamkhani - TriplyDB

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

http://www.wikidata.org/entity/Q34597967

about

Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice Eicosanoid storm in infection and inflammation Niacin, an old drug with a new twist Platelets in patients with aspirin-exacerbated respiratory disease Nicotinic acid receptor agonists differentially activate downstream effectors Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice Prostanoid receptor antagonists: development strategies and therapeutic applications Niacin ameliorates ulcerative colitis via prostaglandin D2-mediated D prostanoid receptor 1 activation.A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.Nicotinic acid activates the capsaicin receptor TRPV1: Potential mechanism for cutaneous flushing.Prostaglandin D2 DP1 receptor is beneficial in ischemic stroke and in acute exicitotoxicity in young and old mice Future of GPR109A agonists in the treatment of dyslipidaemia.Niacin: another look at an underutilized lipid-lowering medication.Role of prostaglandin D2 and the autonomic nervous system in niacin-induced flushing.Recent advances in preventing cardiovascular disorders by managing lipid levels.Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.The flavonoid luteolin inhibits niacin-induced flush Familial hypercholesterolemia: current treatment and advances in management.Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.High dietary niacin may increase prostaglandin formation but does not increase tumor formation in ApcMin/+ mice.Ocular Effects of Niacin: A Review of the Literature.Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans.Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.Biological roles and therapeutic potential of hydroxy-carboxylic Acid receptors.Niacin in cardiovascular disease: recent preclinical and clinical developments A randomized pilot study on the effect of niacin on pulmonary arterial pressure.Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosis.Nicotinic acid: an old drug with a promising future Effects of pyrazole partial agonists on HCA(2) -mediated flushing and VLDL-triglyceride levels in mice.Simvastatin: present and future perspectives.The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin Advances in the management of hyperlipidemia-induced atherosclerosis.Simvastatin: two decades in a circle.High-density lipoprotein cholesterol: current perspective for clinicians.Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.Novel patent publications on high-affinity nicotinic acid receptor agonists.The mechanism and mitigation of niacin-induced flushing.Independent and combined effects of aerobic exercise and pharmacological strategies on serum triglyceride concentrations: a qualitative review.A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.

P2860

Q24600864-6DA82A90-A275-411F-BD6A-17E2AA3439E4 Q26851985-97ACC497-C244-4BF7-A770-27B5F9141195 Q27002774-7A641ED4-FE0E-4495-A132-971536BC0481 Q28080840-D8873186-2D23-4EE2-B21D-AADE47C597BF Q28298974-F762A1E0-397F-45E5-AD07-41DB98E86202 Q28386328-C5E02A78-80CF-4351-9D6F-18D82F96D711 Q33485483-6EEE4E75-6DB7-43C2-BB83-93B62144FC88 Q33625837-4720AC0A-1E10-44AE-9E1D-F586C5706E94 Q33765072-A43F2E1D-7FF2-42B7-9D57-0C16142A5C6A Q33778078-C930433E-1045-4A2D-AA4E-E346A4C3EDBA Q34080404-70A4F05D-6CF8-4CF3-8EC3-1163DB547026 Q34171831-A0712470-8437-4F20-B86B-E3BF4DC0EBA9 Q34255686-C1C6E569-4B61-4235-AC6A-3F0856E66C25 Q34315242-5E7F824E-86BC-4FFD-9492-FD0BA8DA749D Q34343533-208F5B88-E9E2-47F7-98E5-EFF17FBBAAF3 Q34531106-A2116D15-AB6D-40FD-8B54-F5EC5F3E8E9F Q34587640-2677AF20-B3A4-4FD6-9A17-806056C3E8D2 Q34769059-7807CBCB-1F4A-4647-A6DA-698E629A4A57 Q34892917-EE7C922F-05F0-4A7D-9AE7-2EB94A39290E Q35575144-66BCF324-92D4-42A7-96F9-D606A45C5B51 Q35690848-18A8B32F-379C-44F6-8618-CB3E726A52D1 Q35858061-D4139DBE-B81E-44A3-AB83-404F75063499 Q35931525-6D7D0272-C379-4BB8-955D-ED76A3CBF3AC Q35971823-B0A79849-A874-4296-A3DD-60540F3D501B Q36084389-11F01147-8B2A-4B5E-B104-482F4FA7EB9F Q36304121-6FF24102-794E-4E0B-9B20-8E5D39923350 Q36462055-3DF5BCC2-6A53-4F8C-A0DD-B0525FD12B3F Q36497035-363F636E-09FF-4A4D-AB28-EBBCD5E5E7A9 Q36619771-6C639261-8457-452A-86BE-F4CD92ADFBC9 Q36916934-6FDA4BCB-53D0-443A-B129-EEE3EAC41669 Q36983712-F3BBADF9-D375-41DE-99A3-5B4C1C1B12DD Q37019920-6FFAD5B8-4E67-4748-BF63-DB0C3EF617AA Q37104870-5A61EF6E-3A64-4C96-9917-FF4A6CBE8F99 Q37165690-1F52343A-2712-4117-B5C0-BE11F41C6AB1 Q37400405-3393E232-23A2-482E-916F-C696BAAC8CC7 Q37458891-FDDF6147-3116-49EA-A518-B4C865D54342 Q37529810-E0BFB127-6756-425F-89CB-B47B69D4F72F Q37582460-9714CFC7-F466-439D-8C68-3815960A0E4A Q37667487-0073FE55-8720-47FA-8F04-FDC8E4CBC207 Q37689135-9CE42334-6628-4E44-ACDF-E673BAD0D9B0

P2860

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

http://www.wikidata.org/entity/Q34597967

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Antagonism of the prostaglandi ...... sodilation in mice and humans.

@ast

Antagonism of the prostaglandi ...... sodilation in mice and humans.

@en

Antagonism of the prostaglandi ...... sodilation in mice and humans.

@nl

type

label

Antagonism of the prostaglandi ...... sodilation in mice and humans.

@ast

Antagonism of the prostaglandi ...... sodilation in mice and humans.

@en

Antagonism of the prostaglandi ...... sodilation in mice and humans.

@nl

prefLabel

Antagonism of the prostaglandi ...... sodilation in mice and humans.

@ast

Antagonism of the prostaglandi ...... sodilation in mice and humans.

@en

Antagonism of the prostaglandi ...... sodilation in mice and humans.

@nl

P1433

Q34597967-E247FD89-104F-4052-8647-01889A8CD18B

P1476

Q34597967-00E32E44-136D-4E83-A417-1834FAB0D58E

P2093

Q34597967-064949D6-623A-4AE7-A972-0FFCBC784761

Q34597967-1081660F-FC9D-488D-BAC4-63BC5938EFA9

Q34597967-15E7619F-E01B-4E2B-B902-51DFD42CE091

Q34597967-204FA668-2B38-4C9A-891D-FF19C7BABD5A

Q34597967-2A90ECCC-6E15-4BF5-A0BB-586B47EFBC35

Q34597967-512FC70F-E3C6-4545-B5AD-CEFEE55978C2

Q34597967-5DFFDE62-D0BA-4966-8FB6-10376D8B799D

Q34597967-92A59959-CDEF-46E7-A8FF-B59D02E08179

Q34597967-AE8B4735-86C8-4E51-B49E-4F0758C989D5

Q34597967-C95150A6-C869-4CEA-A839-79DD4258A51F

P2860

Q34597967-00B9A1F0-9EAA-4588-95AA-95BECB0D1653

Q34597967-11607B7C-51D2-4D2C-9F2F-87B95F2D6901

Q34597967-24896D4C-5C8A-4507-88F1-BFB493662FC9

Q34597967-2F80E9A1-9D55-4CC9-A08C-61F5EE7C1ABE

Q34597967-2FBDCA62-907C-4CF8-90EE-FE27263554C0

Q34597967-3355A8A6-F93D-4AF2-B32D-90294598F092

Q34597967-35413B09-1536-46E5-80FB-A8FFE0B09921

Q34597967-364E05F4-9BD4-4FD9-A125-26FEFF831AB2

Q34597967-44B68C2A-4BAD-4413-910F-2FA0D97AA972

Q34597967-5A9CBB0F-675D-496B-9BD9-BA03A476BEDD

P304

Q34597967-79C9ADF8-A975-4CF2-8423-8C1F2807CEA7

P31

Q34597967-99587395-4207-49D0-825D-B5F304409BFC

P356

Q34597967-73FBCE23-AF21-4339-95EA-64370044282D

P407

Q34597967-468350D7-688E-4CD5-8667-B9859F89B4D6

P433

Q34597967-B0907272-8E94-4794-A445-3821E5DE4697

P478

Q34597967-26D07F6E-052A-4B8D-9E16-8C5F28A27EE8

P577

Q34597967-61936248-A883-4260-802D-FB092354049C

P5875

Q34597967-C358A615-866F-4DEC-8707-7B0586555DE7

P698

Q34597967-2E213C8C-80FD-47FC-9ADA-D587BEDFA718

P932

Q34597967-8EB701E1-D7A4-418E-9155-5E0F75784CF2

P356

PNAS.0601574103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Antagonism of the prostaglandi ...... sodilation in mice and humans.

@en

P2093

Claudio Sturino

http://www.w3.org/2001/XMLSchema#string

Eseng Lai

http://www.w3.org/2001/XMLSchema#string

Gary O'Neill

http://www.w3.org/2001/XMLSchema#string

Kang Cheng

http://www.w3.org/2001/XMLSchema#string

Kathleen Metters

http://www.w3.org/2001/XMLSchema#string

Keith Gottesdiener

http://www.w3.org/2001/XMLSchema#string

Kenneth K Wu

http://www.w3.org/2001/XMLSchema#string

M Gerard Waters

http://www.w3.org/2001/XMLSchema#string

Samuel D Wright

http://www.w3.org/2001/XMLSchema#string

Tsuei-Ju Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response

Expression and molecular pharmacology of the mouse CRTH2 receptor

Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid

Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans

The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist

Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells

Influence of nicotinic acid on serum cholesterol in man.

P304

6682-6687

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0601574103

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7163347

http://www.w3.org/2001/XMLSchema#string

P698

16617107

http://www.w3.org/2001/XMLSchema#string

P932

1458941

http://www.w3.org/2001/XMLSchema#string